Side-by-side comparison
Bristol-Myers Squibb vs Stryker
As of Sep 25, 2026, P/E is 13.8x for Bristol-Myers Squibb vs 28.2x for Stryker; P/S is 2.6x for Bristol-Myers Squibb vs 4.0x for Stryker; revenue growth is 3.1% for Bristol-Myers Squibb vs 8.5% for Stryker; net margin is 18.9% for Bristol-Myers Squibb vs 14.4% for Stryker.
Key metrics
| Metric | BMY | SYK |
|---|---|---|
| Price | $62.86 | $272.36 |
| Market cap | $128.41B | $104.47B |
| P/E | 13.8x (#1) | 28.2x (#2) |
| P/S | 2.6x (#1) | 4.0x (#2) |
| Revenue growth | 3.1% (#2) | 8.5% (#1) |
| Operating margin | — | 21.4% (#1) |
| Net margin | 18.9% (#1) | 14.4% (#2) |
| Debt / equity | 1.89 (#2) | 0.59 (#1) |
| 1-year return | +42.5% (#1) | -26.2% (#2) |
| Research score | 71/100 (#1) | 56/100 (#2) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Bristol-Myers Squibb Company (BMY) — Drug Manufacturers—General
- Stryker Corporation (SYK) — Medical Devices